UBS Group’s Akcea Therapeutics Inc AKCA Stock Holding History

UBS Group’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$4K	–	8481
2018 Q3	$4K	Buy	+100	New	+$3.03K	﹤0.01%	7609

UBS Group's AKCA Position: Q4 2020 in Review

UBS Group sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 551 shares — an estimated $10K sold.

UBS Group first reported a position in AKCA in Q3 2017 and held it in 12 quarters. The position peaked at $419K in Q3 2019. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

UBS Group reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
UBS Group sold 551 Akcea Therapeutics Inc shares in Q4 2020, an estimated $10K.
UBS Group first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 12 quarters.
UBS Group's Akcea Therapeutics Inc position peaked at $419K in Q3 2019.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.